항우울제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 약물 종류별, 질환 유형별, 약물 유형별, 지역별, 경쟁별(2020-2030년)
Depression Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Disorder Type, By Drug Type, By region, and Competition, 2020-2030F
상품코드:1881438
리서치사:TechSci Research
발행일:2025년 11월
페이지 정보:영문 182 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 항우울제 시장은 2024년 184억 6,000만 달러에서 2030년까지 217억 9,000만 달러로, CAGR 2.8%로 확대될 전망입니다.
이 시장에는 주로 뇌 내 신경전달물질의 작용을 조절하여 작용하는 주요 우울장애 및 관련 정신질환의 치료를 목적으로 개발된 의약품이 포함됩니다. 이러한 시장 확대를 뒷받침하는 주요 요인으로는 전 세계 정신질환 유병률 증가, 정신질환에 대한 대중의 인식 증가로 인한 진단 건수 증가, 지속적인 의약품 연구개발의 발전으로 인한 새로운 치료법 도입 등을 꼽을 수 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
184억 6,000만 달러
시장 규모 : 2030년
217억 9,000만 달러
CAGR : 2025-2030년
2.8%
가장 빠르게 성장하는 부문
브랜드 의약품
최대 시장
북미
주요 시장 촉진요인
우울장애의 유병률 증가는 약물 치료를 필요로 하는 환자 수를 확대시킴으로써 세계 항우울제 시장을 근본적으로 견인하고 있습니다. 이들 질환은 전 세계 질병 부담의 상당 부분을 차지하고 있으며, 효과적인 치료제의 지속적인 공급이 필요합니다.
주요 시장 과제
세계 우울증 치료제 시장의 지속적인 성장을 가로막는 가장 큰 문제는 특히 신흥 경제국에서 정신건강 서비스 및 필수 의약품에 대한 접근성이 제한적이라는 점입니다. 이들 지역에서는 의료 인프라가 부족하고 정신보건 전문가 수가 부족한 것이 자주 문제가 됩니다.
주요 시장 동향
환각제 지원 치료법의 출현은 기존의 모노아민 작용제 접근법을 넘어선 새로운 작용 기전을 제공함으로써 우울증 치료의 지형에 큰 변화를 가져왔습니다. 실로시빈, 리제르브산 디에틸아미드(LSD)와 같은 화합물과 심리적 지지를 결합한 이러한 치료법은 특히 치료 저항성 우울증에서 유망한 효능을 보이고 있습니다.
The Global Depression Drugs Market will grow from USD 18.46 Billion in 2024 to USD 21.79 Billion by 2030 at a 2.8% CAGR. The global depression drugs market encompasses pharmaceutical agents specifically developed to treat major depressive disorder and related mental health conditions, functioning primarily by modulating neurotransmitter activity in the brain. Key drivers bolstering this market's expansion include the escalating global prevalence of mental health disorders, a growing public awareness of these conditions leading to increased diagnoses, and continuous advancements in pharmaceutical research and development introducing novel therapeutic options.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 18.46 Billion
Market Size 2030
USD 21.79 Billion
CAGR 2025-2030
2.8%
Fastest Growing Segment
Branded Drugs
Largest Market
North America
Key Market Drivers
The increasing prevalence of depressive disorders fundamentally propels the global depression drugs market by expanding the patient population requiring pharmacological interventions. These conditions represent a substantial portion of the global disease burden, necessitating a continuous supply of effective treatments. According to the World Health Organization, in September 2025, in their 'World Mental Health Today: Latest Data' and 'Mental Health Atlas 2024' reports, over one billion people worldwide are living with mental health disorders, with anxiety and depressive disorders collectively constituting more than two-thirds of all cases.
Key Market Challenges
A significant challenge impeding the sustained growth of the global depression drugs market is the limited accessibility of mental healthcare services and essential medications, particularly within emerging economies. These regions frequently contend with inadequate healthcare infrastructure and insufficient numbers of mental health professionals. This accessibility gap directly restricts patient reach and the uptake of necessary pharmacological interventions, thereby hindering overall market expansion.
Key Market Trends
The emergence of psychedelic-assisted treatment modalities represents a significant shift in the therapeutic landscape for depression, offering novel mechanisms of action beyond conventional monoaminergic approaches. These therapies, often involving compounds like psilocybin and lysergic acid diethylamide (LSD) alongside psychological support, are demonstrating promising efficacy, particularly for treatment-resistant depression. For instance, Compass Pathways announced in June 2025 that its COMP360 psilocybin achieved the primary endpoint in a Phase 3 trial for treatment-resistant depression, showing a highly statistically significant and clinically meaningful reduction in depressive symptoms after six weeks.
Key Market Players
Otsuka Holdings Co., Ltd.
Pfizer, Inc.
Eli Lilly and Company
AstraZeneca plc.
Novartis AG
Bristol-Myers Squibb Company
GlaxoSmithKline plc.
Takeda Pharmaceutical Co., Ltd.
AbbVie, Inc.
Johnson & Johnson
Report Scope:
In this report, the Global Depression Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies presents in the Global Depression Drugs Market.
Available Customizations:
Global Depression Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Depression Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class (Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Selective Serotonin Reuptake Inhibitors (SSRIs), Central Nervous System (CNS) Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, Others)
5.2.2. By Disorder Type (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, Others)
5.2.3. By Drug Type (Generic Drugs, Branded Drugs)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America Depression Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Disorder Type
6.2.3. By Drug Type
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Depression Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Disorder Type
6.3.1.2.3. By Drug Type
6.3.2. Canada Depression Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Disorder Type
6.3.2.2.3. By Drug Type
6.3.3. Mexico Depression Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Disorder Type
6.3.3.2.3. By Drug Type
7. Europe Depression Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Disorder Type
7.2.3. By Drug Type
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Depression Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Disorder Type
7.3.1.2.3. By Drug Type
7.3.2. France Depression Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Disorder Type
7.3.2.2.3. By Drug Type
7.3.3. United Kingdom Depression Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Disorder Type
7.3.3.2.3. By Drug Type
7.3.4. Italy Depression Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Class
7.3.4.2.2. By Disorder Type
7.3.4.2.3. By Drug Type
7.3.5. Spain Depression Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Class
7.3.5.2.2. By Disorder Type
7.3.5.2.3. By Drug Type
8. Asia Pacific Depression Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Disorder Type
8.2.3. By Drug Type
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Depression Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Disorder Type
8.3.1.2.3. By Drug Type
8.3.2. India Depression Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Disorder Type
8.3.2.2.3. By Drug Type
8.3.3. Japan Depression Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Disorder Type
8.3.3.2.3. By Drug Type
8.3.4. South Korea Depression Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Disorder Type
8.3.4.2.3. By Drug Type
8.3.5. Australia Depression Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Disorder Type
8.3.5.2.3. By Drug Type
9. Middle East & Africa Depression Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Disorder Type
9.2.3. By Drug Type
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Depression Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Disorder Type
9.3.1.2.3. By Drug Type
9.3.2. UAE Depression Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Disorder Type
9.3.2.2.3. By Drug Type
9.3.3. South Africa Depression Drugs Market Outlook
